Publications by authors named "M Veith"

Retinal vein occlusion and its complications are among the most common causes of severe loss of sight in developed countries. In recent years, developments in imaging methods have been introduced, leading to an improvement in diagnostic possibilities. At the same time new treatment options have become available (new intravitreal drugs and treatment protocols, laser and surgical methods).

View Article and Find Full Text PDF

Aim:  Retinal detachment is an acute sight-threatening condition that requires immediate surgical intervention. The aim of this study is to compare the outcomes of pars plana vitrectomy (PPV) for uncomplicated rhegmatogenous retinal detachment (RRD) between the different types of gases used, the position, and the number of tears.

Material And Methods:  This is a retrospective non-randomized comparative study of patients with uncomplicated RRD treated at the Department of Ophthalmology from March 2018 to April 2021 using PPV.

View Article and Find Full Text PDF
Article Synopsis
  • Understanding pathogen diversity is essential for controlling emerging infectious diseases, as different variants interact uniquely with hosts and the environment.
  • This study focuses on Batrachochytrium salamandrivorans (Bsal), a fungal pathogen harming European amphibians, by analyzing 13 isolates to examine their reproductive rates and thermal tolerances.
  • The research suggests that the combination of host body temperature and the thermal range of Bsal can significantly affect pathogen growth, highlighting the importance of identifying pathogen variants to assess risk to host populations.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness of a biosimilar drug, QL1205, compared to the established drug ranibizumab (Lucentis®) in patients with neovascular age-related macular degeneration (nAMD) through a rigorous phase 3 trial.* -
  • A total of 616 treatment-naïve patients were randomly assigned to receive either QL1205 or ranibizumab, and both groups were given injections every four weeks for 48 weeks, with the main focus on changes in best-corrected visual acuity (BCVA).* -
  • Results showed similar improvements in visual acuity for both QL1205 (+6.3 letters) and ranibizumab (+7.
View Article and Find Full Text PDF

This report describes family members with alpha-1 antitrypsin (AAT) deficiency arising from two rare alleles of - p.(Phe76del) and p.(Asp280Val) along with the more common deficiency allele, Pi*Z.

View Article and Find Full Text PDF